一家号称用互联网改造传统医药流通的企业，在盈利增长的情况下，股价却跌穿了发行价，市值蒸发超过300亿。这不是市场的非理性，而是一 场商业模式的彻底败退。 2025年12月17日，药师帮股价收盘于5.62港元。这家曾经市值超过400亿港元的"医药B2B第一股"，如今市值仅剩38亿港元，较2023年8月的历史高点跌去超 过90%。 更令人困惑的是，在公司营收和净利润持续增长的背景下，股价却一路向南。2025年中报显示，药师帮营收98.43亿元，同比增长11.7%，净利润7811.7万 元，同比激增258%。 市场似乎已经看穿了某种本质：药师帮的盈利增长不是来自效率提升，而是源于一种不可持续且可能触碰监管红线的模式。 01 业务模式，从"平台"到"伪平台"的异化过程 药师帮成立于2015年，创始人是前搜房网CTO张步镇。它最初的目标是搭建一个连接药品供应商与终端药店的数字化平台，解决院外医药市场信息不对称、 渠道混乱的问题。 传统的医药流通模式是线性的：药企→总代理→省级经销商→地市级经销商→药店/医疗机构。每个环节都会加价，导致终端价格高企。 一位广东连锁药店老板的经历极为典型：他发现自己通过药师帮采购的"帮力健 ...

Core Viewpoint - The stock of Yaoshi Bang (09885) has seen a significant increase of over 9%, currently trading at 10.55 HKD with a transaction volume of 320 million HKD, driven by positive research from CITIC Securities [1] Group 1: Business Performance - Yaoshi Bang launched its brand-first business in 2020, targeting high-demand product categories and partnering with upstream manufacturers to supply to grassroots medical institutions and pharmacies, achieving an excess gross margin [1] - The GMV of the brand-first business grew by 115.6% year-on-year to 1.08 billion CNY in the first half of 2025, with the self-owned brand GMV increasing by 473.4% year-on-year to 852 million CNY [1] - CITIC Securities believes that the company will continue to steadily increase the proportion of high-margin business, especially after acquiring a pharmaceutical segment that enriches its self-owned product matrix, potentially leading to additional growth [1] Group 2: Product Development and Market Expansion - In 2024, the company plans to launch three "Future Spectrum" series POCT devices, focusing on the grassroots medical institution market to enhance its basic disease detection capabilities [1] - As of June 30, 2025, the company has covered over 18,000 terminal institutions and deployed more than 23,000 units, with plans for accelerated deployment in the second half of 2025 [1] - The POCT devices will be integrated with the clinic's digital management system ("Spectrum Cloud Diagnosis" SaaS system) and AI-assisted systems (Spectrum Smart Doctor), aiming to improve clinic operations and user engagement [1] - The company is actively advancing the application of AI and robotics technology to enhance downstream customer empowerment and supply chain efficiency, which is expected to drive further growth [1]

Core Viewpoint - The stock of Yaoshi Bang (09885) has seen a significant increase of over 9%, driven by strong growth in its proprietary brand business and the introduction of new medical devices aimed at grassroots healthcare institutions [1][2] Group 1: Financial Performance - Yaoshi Bang's proprietary brand business GMV grew by 115.6% year-on-year to 1.08 billion yuan in the first half of 2025, with the higher-margin self-owned brand GMV increasing by 473.4% to 852 million yuan [1] - The company has achieved a trading volume of 320 million Hong Kong dollars, reflecting strong market interest [1] Group 2: Product Development and Market Strategy - In 2024, the company plans to launch three new "Future Spectrum" series POCT devices, focusing on the grassroots healthcare market to enhance its disease detection capabilities [2] - As of June 2025, the company has covered over 18,000 terminal institutions and deployed more than 23,000 units of its POCT devices, with plans for accelerated deployment in the second half of 2025 [2] - The POCT devices will be integrated with the "Spectrum Cloud Diagnosis" SaaS system and AI-assisted systems, aiming to improve clinic management and user engagement [2] Group 3: Future Growth Potential - The company is actively advancing the application of AI and robotics technology to enhance downstream customer capabilities and optimize supply chain efficiency, which is expected to drive further growth [2]